Allergopharma donates DGAKI award at 13th German Allergy Congress

  • Allergopharma supports young researchers with a 5,000 Euro “Allergene Immunotherapy” award by the German Society for Allergology and Clinical Immunology (Deutschen Gesellschaft fuer Allergologie und klinische Immunologie (DGAKI))

Dresden/Reinbek, 22 October 2018 – Allergopharma, the allergy business of Merck, has donated the “Allergene Immunotherapy” award of the German Society for Allergology and Clinical Immunology (DGAKI) for the second time in succession. The award was presented at the end of September at the 13th German Allergy Congress (DAK) in Dresden. Susanne Thum-Oltmer, Director Medical Affairs at Allergopharma, handed over the 5,000 Euro award to Dr. Jose Oteros, from the Centre for Allergy and Environment (ZAUM) of the Technical University and Helmholtz Centre, Munich, for his work “Artemisia pollen is the main vector for airborne endotoxin”. “Only those who think about tomorrow can actively shape the future. We are delighted to be able to present this award this year again,” said Christoph Willers, Vice President Research and Development at Allergopharma. “As a science driven company, we see it as our duty to support young researchers in their work and to promote important projects in allergy research.” The award enables young scientists to advance their research projects.

About the Award

The prize is intended exclusively for special scientific work in the field of allergology and clinical immunology and serves to promote young scientists from the German-speaking countries. It is awarded to projects that deal with diagnostic and therapeutic questions in the field of allergy immunotherapy (AIT). The funding 

must be used for specific projects. If more than one prize-worthy work is submitted, the jury can split the prize.